TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04913090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5610 Tablet （for Part C1）
Description: Tablet(s) administered fasted orally once daily for 1 Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5610 Tablet （for Part C1）
Description: Tablet(s) administered fasted orally once daily for 1 Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5610 Tablet for Part C2
Description: Tablet(s) administered after a high-fat meal orally once daily for 1 Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5610 Tablet for Part C2
Description: Tablet(s) administered after a high-fat meal orally once daily for 1 Day
Study: NCT06053580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 40 mg
Description: Valsartan 40mg twice daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 24 weeks.
Study: NCT04805528

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS)
Description: Twice weekly ALTENS therapy for 12 weeks
Study: NCT05405933

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Propioceptive Neuromuscular Facilitation
Description: Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Balance Exercise
Description: Balance Exercise Along With Conventional Therapy for Balance and Gait
Study: NCT06678139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: Bilateral gastrosoleus stretching, iliopsoas and hamstring stretching (if a shortness is detected), foot intrinsic and extrinsic muscle strengthening, lower extremity muscle strengthening and parkour walking training will be performed. Therapeutic exercises will be performed once a week for 12 weeks under the supervision of a physiotherapist. Parents will be asked to follow a 12-week home exercise program at home during the five days. The home exercise program will include the exercises performed in the pediatric physiotherapy and research laboratory. Parents will be instructed to perform each exercise twice a day at home. Children will be given a weekly exercise diary to increase adherence to the exercise program.
Study: NCT06679335

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lateralization Imagery Training
Description: Lateralization Imagery Training (LIE) is a form of implicit motor imagery that involves determining as accurately and quickly as possible whether an image of a body part belongs to the left or right side. It has been assumed that LIE performance differences reflect changes in central nervous system functioning, errors in judgment, and changes in bodily representations. It has been shown that LIE is a complex mental task that includes cognitive, sensory, motor and behavioral processes and can be associated with them. A study showed that there was a strong correlation between LIE and proprioception.~Within the scope of our study, 3 weeks of training will be provided; Lateralization imagery training will be given every day for the first 2 weeks, and imagery training will be given 3 days a week in the 2nd and 3rd weeks. A total of 20 sessions of treatment will be applied, including 14 sessions of lateralization and 6 sessions of visualization training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateralization Imagery Training
Description: Lateralization Imagery Training (LIE) is a form of implicit motor imagery that involves determining as accurately and quickly as possible whether an image of a body part belongs to the left or right side. It has been assumed that LIE performance differences reflect changes in central nervous system functioning, errors in judgment, and changes in bodily representations. It has been shown that LIE is a complex mental task that includes cognitive, sensory, motor and behavioral processes and can be associated with them. A study showed that there was a strong correlation between LIE and proprioception.~Within the scope of our study, 3 weeks of training will be provided; Lateralization imagery training will be given every day for the first 2 weeks, and imagery training will be given 3 days a week in the 2nd and 3rd weeks. A total of 20 sessions of treatment will be applied, including 14 sessions of lateralization and 6 sessions of visualization training.
Study: NCT05233787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tailored use of defunctioning stoma after TME
Description: Tailored use of defunctioning stoma after TME based on a 2-step process:~i) to perform or not a defunctioning stoma according to the personalized risk of anastomotic leakage (defunctioning stoma only if Anastomotic Failure Observed Risk Score=\[2-6\]), ii) to perform an early stoma closure at day 8-12, according to clinical (fever), biological (CRP level days 2 and 4 postoperatively) and radiological postoperative assessment (CT-scan with colonic contrast retrograde enema day 7-8 postoperatively)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systematic use of defunctioning stoma
Description: Systematic use of defunctioning stoma for 2-3 months after TME, according to French national and international guidelines
Study: NCT04920058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Continuous glucose monitor - a device that monitors blood glucose levels in a continuous closed-loop manner. This can also refer to the process of continuous glucose monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: <Active Comparator?>
Description: \<describe, Comprehensive Wellness Program incorporating a low carbohydrate diet (\<50g/day) and associated education \>

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: <Active Comparator?>
Description: \<describe, Comprehensive Wellness Program incorporating a low carbohydrate diet (\<50g/day) and associated education \>
Study: NCT05171660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: Sintilimab Injection: 200 mg, i.v., D1, Q3W, 8 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Test
Description: XELOX + Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Test
Description: XELOX + Bevacizumab
Study: NCT04839146

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2 Vaccine
Description: SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2 Vaccine
Description: SARS-CoV-2 vaccine
Study: NCT03417206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pupillary dilatation reflex
Description: PRD value will me measured before the start of FESS after 5 minutes of remifentanyl infusion, when PRD sensitivity \> 5% , infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5% and FESS will be started ; intraoperatively infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pupillary dilatation reflex
Description: PRD value will me measured before the start of FESS after 5 minutes of remifentanyl infusion, when PRD sensitivity \> 5% , infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5% and FESS will be started ; intraoperatively infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pupillary dilatation reflex
Description: PRD value will me measured before the start of FESS after 5 minutes of remifentanyl infusion, when PRD sensitivity \> 5% , infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5% and FESS will be started ; intraoperatively infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5%
Study: NCT01733576

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD-tDCS
Study: NCT04329676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Patients with PD who are eligible to bilateral STN DBS surgery and chose to get directSTIM System implanted will be followed over a 6-month period to evaluate changes in their condition.
Study: NCT05722249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Sleep Hygiene
Description: Participants will experience demonstrations and explanations regarding sleep hygiene, mindfulness alerts for at work and mindfulness rest for at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phyical activity and Sleep Hygiene
Description: All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods
Study: NCT05772286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 763SIP8/MPLA-5 vaccine
Description: 763SIP8/MPLA-5 vaccine at day 0, week 8, week 24 and week 48.
Study: NCT05887466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) Low Dose
Description: Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)_Low Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -Low Dose :~   7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) High Dose
Description: Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)_High Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -High Dose :~   1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side.
Study: NCT06199752

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic agent 25 Billion CFU (Nowfoods, USA) , ). Inulin capsules 1000mg Herbamama USA
Description: probiotic agent 25 Billion CFU (Nowfoods, USA), composed of ten strains of bacteria (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantaLactobacillus paracasei, Bifidobacterium breve, Streotococcus thermophiles, Lactobacillus salivarius, and Bifidobacterium longum),

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotic agent 25 Billion CFU (Nowfoods, USA) , ). Inulin capsules 1000mg Herbamama USA
Description: probiotic agent 25 Billion CFU (Nowfoods, USA), composed of ten strains of bacteria (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantaLactobacillus paracasei, Bifidobacterium breve, Streotococcus thermophiles, Lactobacillus salivarius, and Bifidobacterium longum),

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotic agent 25 Billion CFU (Nowfoods, USA) , ). Inulin capsules 1000mg Herbamama USA
Description: probiotic agent 25 Billion CFU (Nowfoods, USA), composed of ten strains of bacteria (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantaLactobacillus paracasei, Bifidobacterium breve, Streotococcus thermophiles, Lactobacillus salivarius, and Bifidobacterium longum),
Study: NCT06549608

Intervention type: DRUG
Intervention: Mavacamten
Description: As per product label
Study: NCT06099002

Intervention type: OTHER
Intervention: Changed Medical research Council,Mini Mental Test, Quadriceps Femoris muscle strength measurement,2 min walking test, fall effectiveness scale,Fall risk self-assessment scale
Description: All individuals were given a respiratory function test to evaluate respiratory functions before and after training Modified Medical research Council to evaluate dyspnea, Mini Mental Test to evaluate cognitive status~, Berg Balance Test to evaluate balance, 2-minute walk test to evaluate walking speed. A hand dynamometer will be used to measure QuadricepsFemoris muscle strength, Fall efficiency scale Fall risk self-assessment scale will be used to evaluate falls.

Intervention type: OTHER
Intervention: Changed Medical research Council,Mini Mental Test, Quadriceps Femoris muscle strength measurement,2 min walking test, fall effectiveness scale,Fall risk self-assessment scale
Description: All individuals were given a respiratory function test to evaluate respiratory functions before and after training Modified Medical research Council to evaluate dyspnea, Mini Mental Test to evaluate cognitive status~, Berg Balance Test to evaluate balance, 2-minute walk test to evaluate walking speed. A hand dynamometer will be used to measure QuadricepsFemoris muscle strength, Fall efficiency scale Fall risk self-assessment scale will be used to evaluate falls.
Study: NCT04775979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenylcyclopropenone (DPCP)
Description: Depigmenting agent
Study: NCT04839146

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2 Vaccine
Description: SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2 Vaccine
Description: SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2 Vaccine
Description: SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2 Vaccine
Description: SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABNCoV2 Vaccine
Description: SARS-CoV-2 vaccine
Study: NCT05419986

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood collection
Description: Molecular monitoring by measure of DNA methylation levels in blood samples collected by fingerstick blood drops, as opposed to veinous phlebotomy

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood collection
Description: Molecular monitoring by measure of DNA methylation levels in blood samples collected by fingerstick blood drops, as opposed to veinous phlebotomy
Study: NCT05149599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae
Description: Saccharomyces cerevisiae, which is a pro-biotic, was given in capsule form, 500mg twice daily for 1 month
Study: NCT06558084

Intervention type: DRUG
Intervention: CDK4/6 Inhibitor
Description: CDK4/6 inhibitor in first and second lines
Study: NCT06189573

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cruciate ligament Reconstruction with autologous quadriceps tendon graft
Description: Surgical reconstruction of anterior cruciate ligament with autologous quadriceps tendon graft

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cruciate ligament Reconstruction with autologous bone patellar tendon bone graft
Description: Surgical reconstruction of anterior cruciate ligament with autologous bone patellar tendon bone graft
Study: NCT06575647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia).~Tafenoquine will be given as follows,~\>10 kg to ≤ 20 kg - 150 mg (1 tab), \>20 kg to ≤ 35 kg - 300 mg (2 tabs), \> 35 kg - 450 mg (3 tabs)
Study: NCT04506086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Participants will receive blinatumomab continuous IV infusion for a maximum of 4 cycles. Each cycle is 6 weeks in duration consisting of 4 weeks of treatment and 2 weeks of rest.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current Wearable Heatlth Monitoring System (CWHMS)
Description: The study will use the CWHMS device to monitor participants' vital signs while they are at home.
Study: NCT05933447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rodatristat Ethyl
Description: Oral, Tablet, 300 mg QD, 300 mg BID, 600 mg BID, 900 mg BID, 900 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral, Tablet, 400 mg QD
Study: NCT06650852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-179
Description: BRII-179 will be given via intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-835 (VIR-2218)
Description: BRII-835 will be given via subcutaneous injection
Study: NCT05933447

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Rodatristat
Description: Oral, Tablet, O mg QD, 0 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Moxifloxacin
Description: Oral, Tablet, 0 mg QD
Study: NCT05312372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination (S095033 + paclitaxel)
Description: Phase 1- dose escalation S095033 ; paclitaxel started at 80 mg/m²,(IV)~Phase 2 - S095033 at RP2D; paclitaxel started at 80 mg/m²,(IV)
Study: NCT05271461

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level laser Therapy
Description: Pin pointed application of low level laser on 15 acupuncture points each point 1 min time of application 15 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circulatory exercises
Description: Active assisted or against mild resistance. Supine with leg up position 18degrees measured by the bed water balance in side rails.~If patient is not comfortable according to the modified Borg scale or contra indicated for the position then assume the supine position.~The subject will have A 3 min rest period to acclimatize themselves to each position.~The ankle pumping exercises consisted of simple repetitions of dorsiflexion 1 sec and planter- flexion for 1 sec with three different exercise intervals:~* repeated dorsiflexion and planter-flexion with no rest (no rest exercise).~* repeated dorsiflexion and planter-flexion with a 2 sec rest period (2 sec rest exercise).~* repeated dorsiflexion and planter-flexion with 4sec rest period (4sec rest exercise).~Subjects will have practiced ankle pumps before the exercise to get familiar and be educated about the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulatory exercises
Description: Active assisted or against mild resistance. Supine with leg up position 18degrees measured by the bed water balance in side rails.~If patient is not comfortable according to the modified Borg scale or contra indicated for the position then assume the supine position.~The subject will have A 3 min rest period to acclimatize themselves to each position.~The ankle pumping exercises consisted of simple repetitions of dorsiflexion 1 sec and planter- flexion for 1 sec with three different exercise intervals:~* repeated dorsiflexion and planter-flexion with no rest (no rest exercise).~* repeated dorsiflexion and planter-flexion with a 2 sec rest period (2 sec rest exercise).~* repeated dorsiflexion and planter-flexion with 4sec rest period (4sec rest exercise).~Subjects will have practiced ankle pumps before the exercise to get familiar and be educated about the procedure.
Study: NCT06241352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin addition to chemotherapy
Description: Chemotherapy was administered along with 80mg of atorvastatin per day. Atorvastatin was discontinued when CA19-9 levels (with CA19-9 negative patients referenced against CEA or CA-125) rose more than 20% above baseline.
Study: NCT06183528

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group (PENG) Block
Description: With ultrasonography-guided PENG block, the femoral, obturator and accessory obturator nerve branches that provide sensory innervation of the anterior surface of the hip joint capsule are blocked .

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pericapsular Nerve Group (PENG) Block
Description: With ultrasonography-guided PENG block, the femoral, obturator and accessory obturator nerve branches that provide sensory innervation of the anterior surface of the hip joint capsule are blocked .
Study: NCT05393427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion
Study: NCT06038175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video Head Impulse Testing
Description: During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient. (Interacoustics EyeSeeCam vHIT 3rd Generation Tests: VOR of lateral, RALP, \& LARP canals. SW: 3rd generation VE525 software. HW: laptop PC, lightweight monocular video goggles). Subjects will be instructed to maintain fixation at a target from 1 m distance. A study team member will deliver at least 5 head impulses per side (10-20° angle, duration 150-200 ms, peak velocity of \>150°/s) in the horizontal and vertical planes with unpredictable timing and direction. A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity. The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team. In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is \<0.8 in the presence of refixation saccades .
Study: NCT02124187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ecig 24 mg nicotine
Description: eCig 24 mg nicotine for 12 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ecig 0 mg nicotine
Description: eCig 0 mg nicotine for 12 weeks